Immucell (ICCC) Amortization of Deferred Charges (2022 - 2026)
Immucell's (ICCC) quarterly Amortization of Deferred Charges came in at $3157.0 in Q4 2025, down 70.79% YoY from $10807.0 in Q4 2024, and down 89.33% on a QoQ basis from $29578.0 in Q3 2025.
Immucell (ICCC) Amortization of Deferred Charges (2022 - 2026) Analysis & Trends
Immucell (ICCC) has 4 years of Amortization of Deferred Charges data on file, last reported at $3157.0 in Q4 2025.
- Quarterly Amortization of Deferred Charges fell 70.79% year-over-year to $3157.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $54347.0 (up 27.38% YoY) and the FY2025 annual result came in at $54348.0, up 27.38% from the prior year.
- Amortization of Deferred Charges eased to $3157.0 in Q4 2025, from $29578.0 in the prior quarter.
- In the past five years, Amortization of Deferred Charges ranged from a high of $29578.0 in Q3 2025 to a low of $1915.0 in Q2 2022.
- A 4-year average of $8358.9 and a median of $10094.0 in 2023 frame the typical range for Amortization of Deferred Charges.
- Annual changes were most pronounced in 2024 — Amortization of Deferred Charges surged 463.11% — and 2025, when it plunged 70.79%.
- Tracing ICCC's Amortization of Deferred Charges over 4 years: stood at $1919.0 in 2022, then soared by 426.0% to $10094.0 in 2023, then rose by 7.06% to $10807.0 in 2024, then sank by 70.79% to $3157.0 in 2025.
- The last three Amortization of Deferred Charges figures came in at $3157.0 (Q4 2025), $29578.0 (Q3 2025), and $10806.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Immucell | 91.19 Mn | 82.33 Mn | 2.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3,157.00 |
| Jun 30, 2026 | 3,157.00 |
| Dec 31, 2025 | 3,157.00 |
| Dec 31, 2025 | 3,157.00 |
| Sep 30, 2025 | 29,578.00 |
| Sep 30, 2025 | 29,578.00 |
| Jun 30, 2025 | 10,806.00 |
| Jun 30, 2025 | 10,806.00 |
| Mar 31, 2025 | 10,806.00 |
| Mar 31, 2025 | 10,806.00 |
| Dec 31, 2024 | 10,807.00 |
| Dec 31, 2024 | 10,807.00 |
| Sep 30, 2024 | 10,805.00 |
| Sep 30, 2024 | 10,805.00 |
| Jun 30, 2024 | 10,806.00 |
| Jun 30, 2024 | 10,806.00 |
| Mar 31, 2024 | 10,247.00 |
| Mar 31, 2024 | 10,247.00 |
| Dec 31, 2023 | 10,094.00 |
| Dec 31, 2023 | 10,094.00 |